TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20708076

Group type: EXPERIMENTAL
Intervention: Mucoadhesive tablet containing 24 μg clobetasol‐17 propionate (CP) applied 3 times a day for 4 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Commercial CP ointment for cutaneous application (123 μg/application) mixed with Orabase™
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 16
Study: 18534050

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily for 28 days
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 14660211

Group type: EXPERIMENTAL
Intervention: PErforM program (Experimental group)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 11443835

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment using Subjective Global Assessment
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Risk factors for malnutrition
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Nutritional screening and/or assessment
Number of subjects: 374
Study: 9051558

Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg three times daily for 10 days)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 8391756

Group type: EXPERIMENTAL
Intervention: Salmonella abortus equi endotoxin (0.4 ng/kg body wt)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3085560

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of epinephrine and aminophylline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 31356228

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m (C20)
Number of subjects: 35
Study: 28574378

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching from atorvastatin to rosuvastatin after 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin and rosuvastatin (without switching)
Number of subjects: 0
Study: 26571012

Group type: EXPERIMENTAL
Intervention: Inulin (30 g/day for 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cellulose (control)
Number of subjects: 40
Study: 24710248

Group type: EXPERIMENTAL
Intervention: SLIPA
Number of subjects: 124

Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 124
Study: 22781876

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 998
Study: 19165412

Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic ureteral catheterization
Number of subjects: 1583

Group type: COMPARATOR
Intervention: No prophylactic ureteral catheterization
Number of subjects: 1583
Study: 17578359

Group type: EXPERIMENTAL
Intervention: Monsel's solution
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study: 15368689

Group type: EXPERIMENTAL
Intervention: Ligasure device for radical prostatectomy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ligasure device for radical cystectomy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional ligation for radical prostatectomy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional ligation for radical cystectomy
Number of subjects: 58
Study: 11108415

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing 20 g of protein and 800 mg of calcium for 60 days
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 171
Study: 9092165

Group type: EXPERIMENTAL
Intervention: Endoprosthesis of biocompatible polymers
Number of subjects: 15

Group type: COMPARATOR
Intervention: Endoprosthesis of silicon rubber
Number of subjects: 15
Study: 8382934

Group type: EXPERIMENTAL
Intervention: Single dose of OPC‐17116 (400 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Repeated doses of OPC‐17116 (400 mg day‐1, twice daily, for 6.5 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: OPC‐17116 (300 mg day‐1, three times daily, for 2 days)
Number of subjects: 15
Study: 3455717

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus ACNU
Number of subjects: 77
Study: 31915883

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761®
Number of subjects: 202
Study: 29506685

Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 339
Study: 27929530

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (⩾5 min)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) (<20 s)
Number of subjects: 73
Study: 26209097

Group type: EXPERIMENTAL
Intervention: Risk factor guided multi-component intervention including medication adjustment, stepped care for anxiety/depression, and exercise therapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factor guided multi-component intervention
Number of subjects: 0
Study: 24257456

Group type: EXPERIMENTAL
Intervention: Orsiro Hybrid sirolimus‐eluting stent
Number of subjects: 375

Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus‐eluting stent
Number of subjects: 375
Study: 20367790

Group type: EXPERIMENTAL
Intervention: CR-rhIFN-α(2b) 160 μg every 2 weeks for 12 weeks with ribavirin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CR-rhIFN-α(2b) 320 μg every 2 weeks for 12 weeks with ribavirin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CR-rhIFN-α(2b) 480 μg every 2 weeks for 12 weeks with ribavirin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CR-rhIFN-α(2b) 640 μg every 2 weeks for 12 weeks with ribavirin
Number of subjects: 32
Study: 18719760

Group type: EXPERIMENTAL
Intervention: Transdisciplinary care
Number of subjects: 153

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 153
Study: 17166806

Group type: COMPARATOR
Intervention: Bimanual tasks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Unimanual tasks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Optimal trajectories
Number of subjects: 26
Study: 12877758

Group type: EXPERIMENTAL
Intervention: β1-selective β-blockers (nebivolol)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: DHPCCB (amlodipine, felodipine, isradipine, nifedipine)
Number of subjects: 171
Study: 10741935

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 201
Study: 8941053

Group type: EXPERIMENTAL
Intervention: Seprafilm (HAL-F)
Number of subjects: 127

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 127
Study: 1313078

Group type: EXPERIMENTAL
Intervention: L-threonine (2 g daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31500139

Group type: EXPERIMENTAL
Intervention: Endurance training with carbohydrate administration before each session
Number of subjects: 23

Group type: COMPARATOR
Intervention: Endurance training without carbohydrate administration
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Endurance training with carbohydrate administration
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 23
Study: 28294318

Group type: EXPERIMENTAL
Intervention: Impact of Killing (IOK) treatment (N = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 6-week waitlist condition (Control, N = 16)
Number of subjects: 33
Study: 25728731

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRAs) therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: No MRA therapy
Number of subjects: 151
Study: 24026142

Group type: EXPERIMENTAL
Intervention: ramipril (ACE‐I)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: losartan (ARB)
Number of subjects: 439

Group type: COMPARATOR
Intervention: hydrochlorothiazide (diuretic)
Number of subjects: 439

Group type: COMPARATOR
Intervention: amlodipine (CCB)
Number of subjects: 439
Study: 22174074

Group type: EXPERIMENTAL
Intervention: Topical administration of standardized extract from Ageratina pichinchensis
Number of subjects: 34

Group type: COMPARATOR
Intervention: 7% propylene glycol alginate (control)
Number of subjects: 34
Study: 19356392

Group type: EXPERIMENTAL
Intervention: TDS-testosterone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Androgel
Number of subjects: 12
Study: 18025807

Group type: EXPERIMENTAL
Intervention: 20% glycerol-based emollient
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glycerol-free placebo
Number of subjects: 24
Study: 16159535

Group type: EXPERIMENTAL
Intervention: 1-month tapering of antiepileptic drug
Number of subjects: 57

Group type: COMPARATOR
Intervention: 6-month tapering of antiepileptic drug
Number of subjects: 57
Study: 12447120

Group type: EXPERIMENTAL
Intervention: Baby walkers
Number of subjects: 0

Group type: COMPARATOR
Intervention: No baby walkers (control group)
Number of subjects: 0
Study: 9894689

Group type: EXPERIMENTAL
Intervention: Comfortable position during object manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small target condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pinpoint target condition
Number of subjects: 0
Study: 7573271

Group type: COMPARATOR
Intervention: Management without seizure prophylaxis
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Chronic hypertension with superimposed preeclampsia
Number of subjects: 467
Study: 1963701

Group type: EXPERIMENTAL
Intervention: CDDP 200 mg/m2 administered in arm A (100 mg/m2 on Day 1 and Day 8)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CDDP 200 mg/m2 administered in arm B (40 mg/m2 per day during 5 consecutive days)
Number of subjects: 57
Study: 6992711

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 80
Study: 30417710

Group type: COMPARATOR
Intervention: ART-Def
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART-Immed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-exposed-uninfected
Number of subjects: 0
Study: 28162873

Group type: EXPERIMENTAL
Intervention: Loop drainage
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard incision & drainage (I&D)
Number of subjects: 46
Study: 25690082

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24330656

Group type: EXPERIMENTAL
Intervention: Modified visual probe task with attentional retraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups received 21 mg transdermal nicotine patches for 8-12 weeks and withdrawal-oriented behavioural support for 7 sessions
Number of subjects: 0
Study: 20562711

Group type: EXPERIMENTAL
Intervention: Combined aerobic plus strength training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aerobic interval training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 19302015

Group type: EXPERIMENTAL
Intervention: Active LEDT cluster-probe (660/850 nm, 10/30 mW)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo cluster-probe with no output
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single-diode 810-nm 200-mW laser
Number of subjects: 8
Study: 16421747

Group type: EXPERIMENTAL
Intervention: Early neuromuscular customized training (ETG) starting 2 weeks after surgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional training (CG) starting 6 weeks after surgery
Number of subjects: 56
Study: 15191483

Group type: EXPERIMENTAL
Intervention: Bra
Number of subjects: 58

Group type: COMPARATOR
Intervention: Binder
Number of subjects: 58
Study: 11330759

Group type: EXPERIMENTAL
Intervention: Second-line drugs treatment for six months
Number of subjects: 24
Study: 8979282

Group type: EXPERIMENTAL
Intervention: AA + DHA formula (0.12 wt% DHA and 0.43 wt% AA from egg yolk phospholipid)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: DHA formula (0.2 wt% DHA from fish oil)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control formula (no added LCP fatty acids)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Breast-fed group
Number of subjects: 197
Study: 8163425

Group type: EXPERIMENTAL
Intervention: Silicone breast implants
Number of subjects: 0
Study: 2438878

Group type: EXPERIMENTAL
Intervention: Isotretinoin (Roaccutane) for 8 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Etretinate (Tigason) for 8 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 29395632

Group type: EXPERIMENTAL
Intervention: Education on symptoms management and training modifications
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Education+Exercise program
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Education+Gait retraining
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Education component (common to all interventions)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 58
Study: 27113123

Group type: EXPERIMENTAL
Intervention: Supported employment services
Number of subjects: 449
Study: 25659620

Group type: EXPERIMENTAL
Intervention: Combined physical exercise training and nutritional intervention (EN group, n = 30)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Exercise training only (E group, n = 28)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (C, n = 31)
Number of subjects: 89
Study: 23089188

Group type: EXPERIMENTAL
Intervention: Prolonged burst pacing without analgesia and sedation (Group B)
Number of subjects: 104

Group type: COMPARATOR
Intervention: T‐wave shock under analgesia and sedation (Group T)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Neuron‐specific enolase levels after 6, 24, and 48 h (both groups)
Number of subjects: 104
Study: 21905250

Group type: COMPARATOR
Intervention: Placebo arm of a 2-year study
Number of subjects: 622
Study: 19140498

Group type: EXPERIMENTAL
Intervention: Tibolone therapy (2.5 mg daily for 1 year)
Number of subjects: 26
Study: 17043253

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional hemostasis (CH)
Number of subjects: 100
Study: 12883103

Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioral therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 60
Study: 10575080

Group type: EXPERIMENTAL
Intervention: Unconstrained compensatory stepping evoked by platform translation (no specific instructions)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Constrained compensatory stepping cued by platform translation (prior instruction to step rapidly)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rapid voluntary stepping to a light cue
Number of subjects: 5
Study: 8571194

Group type: EXPERIMENTAL
Intervention: Rapid protamine administration (1.5 mg/kg over 3 minutes)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Slow protamine administration (1.5 mg/kg over 15 minutes)
Number of subjects: 15
Study: 1929241

Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (0.25 mg/kg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (1.5 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6886033

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 29
Study: 31797473

Group type: EXPERIMENTAL
Intervention: Crocin (30 mg/day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Saffron aqueous extract (SAE) (30 mg/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 31586644

Group type: EXPERIMENTAL
Intervention: SRP + aPDT (photodynamic therapy)
Number of subjects: 114

Group type: COMPARATOR
Intervention: SRP (control group)
Number of subjects: 114
Study: 29478239

Group type: EXPERIMENTAL
Intervention: PF-06669571 (1 mg to 3 mg over 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PF-06669571
Number of subjects: 20

Group type: COMPARATOR
Intervention: PF-06669571 and Placebo
Number of subjects: 20
Study: 27693003

Group type: EXPERIMENTAL
Intervention: 10 puffs of e-cigarette vapor (ECV) for 10 minutes
Number of subjects: 16
Study: 25274899

Group type: EXPERIMENTAL
Intervention: Intravenous tanezumab 5 mg
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Intravenous tanezumab 10 mg
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1668
Study: 23113833

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin daily plus SAR236553 once every 2 weeks
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin daily plus SAR236553 once every 2 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: 80 mg of atorvastatin daily plus placebo once every 2 weeks
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SAR236553 (combined with atorvastatin)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 80 mg of atorvastatin plus placebo
Number of subjects: 92
Study: 20352415

Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 400 mg modafinil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18845960

Group type: EXPERIMENTAL
Intervention: Antiretroviral-naive mothers and infants
Number of subjects: 980

Group type: COMPARATOR
Intervention: Single-dose nevirapine or perinatal zidovudine treatment
Number of subjects: 980
Study: 15911239

Group type: COMPARATOR
Intervention: Glutamine levels at Day 0 in patients with ALL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glutamine levels in Group M (CNS disease present)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glutamine and asparagine concentrations at Day 14 in Group L
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glutamic acid amounts at Day 14 in Group L
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glutamine levels at Day 42 in Group M
Number of subjects: 45
Study: 12621013

Group type: EXPERIMENTAL
Intervention: CCK infusion at 0.40 IDU/kg over 20 min
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CCK infusion at 0.40 IDU/kg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Comparison of two DCG studies in phase 3
Number of subjects: 44
Study: 10836213

Group type: EXPERIMENTAL
Intervention: CPB at 28 degrees C (Group H)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CPB at 32 degrees C (Group M)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Normothermia (>36 degrees C) (Group N)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Overall comparison of sjvO2 and a-jvO2
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sjv(lactate)
Number of subjects: 24
Study: 8656155

Group type: EXPERIMENTAL
Intervention: Shared attributes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Shared causal relations
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Binding causal relations
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Noncausal relation and familiar animal categories
Number of subjects: 5
Study: 1462984

Group type: EXPERIMENTAL
Intervention: 99mTc diethylene-triamine pentaacetic acid (Tc-DTPA) GFR estimation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Estimation using the equation of Cockcroft and Gault
Number of subjects: 24
Study: 3970797

Group type: EXPERIMENTAL
Intervention: Atropine combined with methohexitone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate combined with methohexitone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine combined with thiopentone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 0
Study: 30601885

Group type: EXPERIMENTAL
Intervention: NCES and NDCS (subgroup 1B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NCES (subgroup 1A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NCES (subgroup 2A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NCES and NDCS (subgroup 2B)
Number of subjects: 40
Study: 29582891

Group type: EXPERIMENTAL
Intervention: Consumption of farmed salmon three times a week during 23 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control meal (meat) three times a week during 23 weeks
Number of subjects: 84
Study: 30640988

Group type: EXPERIMENTAL
Intervention: Sub-hyperthermia foot bath with syndrome typing of Chinese medicine (CM), 30 min each time, once per day for 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine treatment of Western medicine (WM)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sub-hyperthermia foot bath with syndrome typing of Chinese medicine (CM)
Number of subjects: 120
Study: 24473372

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (80 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study: 22532661

Group type: EXPERIMENTAL
Intervention: High concentration oxygen (8 L/min via medium concentration mask)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Titrated oxygen (to achieve oxygen saturations between 93 and 95%)
Number of subjects: 150
Study: 20822038

Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 18773728

Group type: EXPERIMENTAL
Intervention: Subliminal presentation of famous attractive faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal presentation of unfamiliar attractive faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal presentation of unfamiliar less attractive faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supraliminal presentation of faces
Number of subjects: 0
Study: 15705007

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg b.i.d.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35